+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Minimal Residual Disease (MRD) Testing Market Size, Share, Forecast, And Trends Analysis - Global Forecast to 2036- Product Image
Minimal Residual Disease (MRD) Testing Market Size, Share, Forecast, And Trends Analysis - Global Forecast to 2036- Product Image
New

Minimal Residual Disease (MRD) Testing Market Size, Share, Forecast, And Trends Analysis - Global Forecast to 2036

  • PDF Icon

    Report

  • 218 Pages
  • September 2026
  • Region: Global
  • Meticulous Market Research Pvt. Ltd.
  • ID: 6031544
Description Jump to:
The minimal residual disease (MRD) testing market is projected to reach $13.6 billion by 2036 from an estimated $2.7 billion in 2026, at a CAGR of 17.5% from 2026 to 2036. The market stood at $2.3 billion in 2025. The growth of this market is primarily fueled by the growing incidence of cancer and rising survival rates, the establishment of MRD as a regulatory endpoint supporting accelerated drug approval, and expanding Medicare coverage for molecular diagnostics. Additionally, rising adoption of personalized treatments and targeted therapies in oncology, growing use of MRD testing in solid tumors, and the consolidation of digital PCR technology among established molecular diagnostics companies are expected to create substantial growth opportunities for market participants.

The key players operating in the minimal residual disease testing market are Natera, Inc. (U.S.), Adaptive Biotechnologies Corporation (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Bio Rad Laboratories, Inc. (U.S.), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN N.V. (Netherlands), Guardant Health, Inc. (U.S.), NeoGenomics Laboratories, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Exact Sciences Corporation (U.S.), Integrated DNA Technologies, Inc. (U.S.), Twist Bioscience Corporation (U.S.), Sysmex Corporation (Japan), and Invivoscribe, Inc. (U.S.).

The minimal residual disease testing market study presents historical market data value (2023 and 2024), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, technology, application, sample type, customer type, and geography.

Among all the offerings, the assays & reagents segment is expected to account for the largest share of the minimal residual disease testing market in 2026. The dominant position of this segment is primarily attributed to the serial nature of MRD monitoring, in which reagents are consumed at every testing timepoint over the course of a patient's treatment and surveillance. Software & services is projected to register the highest growth, supported by the interpretive demands of classifying low-signal results against reference datasets.

Among all the technologies, the next generation sequencing segment is expected to account for the largest share of the minimal residual disease testing market in 2026, the highest among all technology segments. This dominance is reinforced by the technology's explicit naming, alongside flow cytometry based methods, as a qualifying approach in the FDA's draft guidance defining the MRD regulatory endpoint. Flow cytometry also maintains a strong position in the market given its established clinical role.

Among all the applications, the blood cancers segment is expected to account for the largest share of the minimal residual disease testing market in 2026, given the well-established use of MRD testing in leukemia, lymphoma, and multiple myeloma. The solid tumors segment is projected to register the higher CAGR, at 18.7%, as coverage determinations extend from post-surgical surveillance into treatment response monitoring during active systemic therapy.

Among all the sample types, the blood segment is projected to hold the largest market share in 2026. This segment's dominance stems from its suitability for serial monitoring at frequencies bone marrow aspiration cannot support, along with its role as the practical sample choice for solid tumor MRD assessment. Bone marrow holds a 36.0% share, reinforced by its specification in the FDA's draft guidance for assessment of the regulatory endpoint.

Among all the customer types, the pharmaceutical & biopharmaceutical companies segment is projected to register significant growth during the forecast period, accounting for the largest customer share at 38.0% in 2026 and the highest growth rate, as MRD assessment becomes a required component of registrational trial design in multiple myeloma.

Among all the geographies, North America is expected to account for the largest regional share in 2026, supported by the Molecular Diagnostic Services Program, the only assay-specific reimbursement framework for MRD testing among the geographies studied, and by the region's host of the two largest laboratory service providers, Natera and Adaptive Biotechnologies. Asia-Pacific is also projected to register the highest CAGR during the forecast period of 2026-2036, driven by rising diagnostic adoption across the region even as no assay-specific coverage framework equivalent to the Molecular Diagnostic Services Program currently operates there.

Key Questions Answered in the Report:

  • What is the current revenue generated by the minimal residual disease testing market globally?
  • At what rate is the minimal residual disease testing market demand projected to grow for the next 10 years?
  • What are the historical market sizes and growth rates of the minimal residual disease testing market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of offering, technology, application, sample type, and customer type are expected to create major traction for the manufacturers in this market?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the minimal residual disease testing market?
  • Who are the major players in the minimal residual disease testing market? What are their specific product offerings in this market?
  • What are the recent strategic developments in the minimal residual disease testing market? What are the impacts of these strategic developments on the market?

Table of Contents

1 Introduction
1.1 Market Definition
1.2 Market Ecosystem
1.3 Currency & Limitations
1.4 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection & Validation Process
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Sizing & Forecasting
2.3.1 Market Size Estimation Approach
2.3.2 Growth Forecast Approach
2.4 Assumptions for the Study
3 Executive Summary
3.1 Market Overview
3.2 Market Dynamics
3.3 Segmental Analysis
3.3.1 By Offering
3.3.2 By Technology
3.3.3 By Application
3.3.4 By Sample Type
3.3.5 By Customer Type
3.3.6 By Geography
3.4 Competitive Landscape
4 Market Insights
4.1 Overview
4.2 Factors Affecting Market Growth
4.2.1 Drivers
4.2.1.1 Growing Incidence of Cancer
4.2.1.2 Establishment of MRD as an Endpoint Supporting Accelerated Approval
4.2.1.3 Increasing Investments & Funding for MRD Testing & Research
4.2.2 Restraints
4.2.2.1 High Costs of Minimal Residual Disease Testing
4.2.3 Opportunities
4.2.3.1 Rising Adoption of Personalized Treatments & Targeted Therapies in the Field of Oncology
4.2.3.2 Growing Use of MRD Testing in Cases of Solid Tumors
4.2.4 Challenges
4.2.4.1 Chances of False Positive/Negative Results
4.2.5 Trends
4.2.5.1 Consolidation of Digital PCR
4.2.5.2 Whole Genome and Methylation Based MRD Detection
4.2.5.3 Integration of Artificial Intelligence into MRD Interpretation
4.3 Regulatory Analysis
4.3.1 North America
4.3.1.1 U.S.
4.3.1.2 Canada
4.3.2 Europe
4.3.3 Asia Pacific
4.3.3.1 China
4.3.3.2 Japan
4.3.3.3 India
4.3.4 Latin America
4.3.5 Middle East & Africa
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Buyers
4.4.2 Bargaining Power of Suppliers
4.4.3 Threat of Substitutes
4.4.4 Threat of New Entrants
4.4.5 Degree of Competition
4.5 Technology Evolution Roadmap
5 Market Assessment, By Offering
5.1 Overview
5.2 Assays & Reagents
5.3 Instruments
5.4 Software & Services
6 Market Assessment, By Technology
6.1 Overview
6.2 Flow Cytometry
6.3 Polymerase Chain Reaction
6.4 Next Generation Sequencing
6.5 Other Technologies
7 Market Assessment, By Application
7.1 Overview
7.2 Blood Cancers
7.2.1 Lymphoma
7.2.2 Leukemia
7.2.2.1 Acute Lymphoblastic Leukemia (ALL)
7.2.2.2 Chronic Lymphocytic Leukemia (CLL)
7.2.2.3 Other Leukemias
7.2.3 Multiple Myeloma
7.2.4 Other Blood Cancers
7.3 Solid Tumors
8 Market Assessment, By Sample Type
8.1 Overview
8.2 Blood
8.3 Bone Marrow
8.4 Other Sample Types
9 Market Assessment, By Customer Type
9.1 Overview
9.2 Pharmaceutical & Biopharmaceutical Companies
9.3 Hospitals
9.4 Diagnostic Laboratories
9.5 Academic & Research Organizations/Institutions
10 Market Assessment, By Geography
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 Switzerland
10.3.7 Netherlands
10.3.8 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 South Korea
10.4.5 Australia
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
11 Competitive Landscape
11.1 Overview
11.2 Key Growth Strategies
11.3 Competitive Benchmarking
11.4 Competitive Dashboard
11.4.1 Industry Leaders
11.4.2 Market Differentiators
11.4.3 Vanguards
11.4.4 Emerging Companies
11.5 Market Share Analysis
11.5.1 Natera, Inc. (U.S.)
11.5.2 F. Hoffmann La Roche Ltd. (Switzerland)
11.5.3 Bio Rad Laboratories, Inc. (U.S.)
11.5.4 Adaptive Biotechnologies Corporation (U.S.)
12 Company Profiles
12.1 Natera, Inc.
12.2 Adaptive Biotechnologies Corporation
12.3 F. Hoffmann La Roche Ltd.
12.4 Bio Rad Laboratories, Inc.
12.5 Illumina, Inc.
12.6 Thermo Fisher Scientific Inc.
12.7 QIAGEN N.V.
12.8 Guardant Health, Inc.
12.9 NeoGenomics Laboratories, Inc.
12.10 Myriad Genetics, Inc.
12.11 Exact Sciences Corporation
12.12 Integrated DNA Technologies, Inc.
12.13 Twist Bioscience Corporation
12.14 Sysmex Corporation
12.15 Invivoscribe, Inc.
(Each Profile Covers Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)
13 Appendix
13.1 Available Customization
13.2 Questions Answered in This Report
13.3 Related Reports
13.4 About Meticulous Research
List of Tables
Table 1 Cancer Recurrence Rates, By Cancer Type
Table 2 FDA Approved Personalized Therapies For Cancer
Table 3 Regulatory Authorities Governing IVD, Flow Cytometry, PCR, And NGS Products, By Country/Region
Table 4 Global Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 5 Global Minimal Residual Disease Testing Assays & Reagents Market, By Country/Region, 2024 To 2036 (USD Million)
Table 6 Global Minimal Residual Disease Testing Instruments Market, By Country/Region, 2024 To 2036 (USD Million)
Table 7 Global Minimal Residual Disease Testing Software & Services Market, By Country/Region, 2024 To 2036 (USD Million)
Table 8 Global Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 9 Global Flow Cytometry Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
Table 10 Global PCR Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
Table 11 Global NGS Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
Table 12 Global Minimal Residual Disease Testing Market For Other Technologies, By Country/Region, 2024 To 2036 (USD Million)
Table 13 Global Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 14 Global Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 15 Global Minimal Residual Disease Testing Market For Blood Cancers, By Country/Region, 2024 To 2036 (USD Million)
Table 16 Global Minimal Residual Disease Testing Market For Lymphoma, By Country/Region, 2024 To 2036 (USD Million)
Table 17 Global Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 18 Global Minimal Residual Disease Testing Market For Leukemia, By Country/Region, 2024 To 2036 (USD Million)
Table 19 Global Minimal Residual Disease Testing Market For Acute Lymphoblastic Leukemia, By Country/Region, 2024 To 2036 (USD Million)
Table 20 Global Minimal Residual Disease Testing Market For Chronic Lymphocytic Leukemia, By Country/Region, 2024 To 2036 (USD Million)
Table 21 Global Minimal Residual Disease Testing Market For Other Leukemias, By Country/Region, 2024 To 2036 (USD Million)
Table 22 Global Minimal Residual Disease Testing Market For Multiple Myeloma, By Country/Region, 2024 To 2036 (USD Million)
Table 23 Global Minimal Residual Disease Testing Market For Other Blood Cancers, By Country/Region, 2024 To 2036 (USD Million)
Table 24 Global Minimal Residual Disease Testing Market For Solid Tumors, By Country/Region, 2024 To 2036 (USD Million)
Table 25 Global Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 26 Global Blood Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
Table 27 Global Bone Marrow Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
Table 28 Global Other Samples Based Minimal Residual Disease Testing Market, By Country/Region, 2024 To 2036 (USD Million)
Table 29 Global Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 30 Global Minimal Residual Disease Testing Market For Pharmaceutical & Biopharmaceutical Companies, By Country/Region, 2024 To 2036 (USD Million)
Table 31 Global Minimal Residual Disease Testing Market For Hospitals, By Country/Region, 2024 To 2036 (USD Million)
Table 32 Global Minimal Residual Disease Testing Market For Diagnostic Laboratories, By Country/Region, 2024 To 2036 (USD Million)
Table 33 Global Minimal Residual Disease Testing Market For Academic & Research Organizations/Institutions, By Country/Region, 2024 To 2036 (USD Million)
Table 34 Global Minimal Residual Disease Testing Market, By Geography, 2024 To 2036 (USD Million)
Table 35 North America: Minimal Residual Disease Testing Market, By Country, 2024 To 2036 (USD Million)
Table 36 North America: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 37 North America: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 38 North America: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 39 North America: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 40 North America: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 41 North America: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 42 North America: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 43 U.S.: Estimated Number Of New Cancer Cases By Type & State
Table 44 U.S.: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 45 U.S.: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 46 U.S.: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 47 U.S.: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 48 U.S.: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 49 U.S.: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 50 U.S.: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 51 Canada: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 52 Canada: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 53 Canada: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 54 Canada: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 55 Canada: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 56 Canada: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 57 Canada: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 58 Europe: Minimal Residual Disease Testing Market, By Country, 2024 To 2036 (USD Million)
Table 59 Europe: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 60 Europe: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 61 Europe: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 62 Europe: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 63 Europe: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 64 Europe: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 65 Europe: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 66 Germany: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 67 Germany: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 68 Germany: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 69 Germany: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 70 Germany: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 71 Germany: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 72 Germany: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 73 U.K.: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 74 U.K.: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 75 U.K.: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 76 U.K.: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 77 U.K.: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 78 U.K.: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 79 U.K.: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 80 France: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 81 France: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 82 France: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 83 France: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 84 France: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 85 France: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 86 France: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 87 Italy: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 88 Italy: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 89 Italy: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 90 Italy: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 91 Italy: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 92 Italy: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 93 Italy: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 94 Spain: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 95 Spain: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 96 Spain: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 97 Spain: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 98 Spain: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 99 Spain: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 100 Spain: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 101 Switzerland: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 102 Switzerland: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 103 Switzerland: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 104 Switzerland: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 105 Switzerland: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 106 Switzerland: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 107 Switzerland: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 108 Netherlands: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 109 Netherlands: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 110 Netherlands: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 111 Netherlands: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 112 Netherlands: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 113 Netherlands: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 114 Netherlands: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 115 Rest Of Europe: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 116 Rest Of Europe: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 117 Rest Of Europe: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 118 Rest Of Europe: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 119 Rest Of Europe: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 120 Rest Of Europe: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 121 Rest Of Europe: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 122 Asia Pacific: Minimal Residual Disease Testing Market, By Country, 2024 To 2036 (USD Million)
Table 123 Asia Pacific: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 124 Asia Pacific: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 125 Asia Pacific: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 126 Asia Pacific: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 127 Asia Pacific: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 128 Asia Pacific: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 129 Asia Pacific: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 130 China: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 131 China: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 132 China: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 133 China: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 134 China: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 135 China: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 136 China: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 137 Japan: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 138 Japan: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 139 Japan: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 140 Japan: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 141 Japan: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 142 Japan: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 143 Japan: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 144 India: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 145 India: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 146 India: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 147 India: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 148 India: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 149 India: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 150 India: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 151 South Korea: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 152 South Korea: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 153 South Korea: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 154 South Korea: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 155 South Korea: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 156 South Korea: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 157 South Korea: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 158 Australia: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 159 Australia: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 160 Australia: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 161 Australia: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 162 Australia: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 163 Australia: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 164 Australia: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 165 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 166 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 167 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 168 Rest Of Asia Pacific: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 169 Rest Of Asia Pacific: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 170 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 171 Rest Of Asia Pacific: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 172 Latin America: Minimal Residual Disease Testing Market, By Country, 2024 To 2036 (USD Million)
Table 173 Latin America: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 174 Latin America: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 175 Latin America: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 176 Latin America: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 177 Latin America: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 178 Latin America: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 179 Latin America: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 180 Brazil: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 181 Brazil: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 182 Brazil: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 183 Brazil: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 184 Brazil: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 185 Brazil: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 186 Brazil: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 187 Mexico: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 188 Mexico: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 189 Mexico: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 190 Mexico: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 191 Mexico: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 192 Mexico: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 193 Mexico: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 194 Rest Of Latin America: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 195 Rest Of Latin America: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 196 Rest Of Latin America: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 197 Rest Of Latin America: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 198 Rest Of Latin America: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 199 Rest Of Latin America: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 200 Rest Of Latin America: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 201 Middle East & Africa: Minimal Residual Disease Testing Market, By Offering, 2024 To 2036 (USD Million)
Table 202 Middle East & Africa: Minimal Residual Disease Testing Market, By Technology, 2024 To 2036 (USD Million)
Table 203 Middle East & Africa: Minimal Residual Disease Testing Market, By Application, 2024 To 2036 (USD Million)
Table 204 Middle East & Africa: Minimal Residual Disease Testing Market For Blood Cancers, By Type, 2024 To 2036 (USD Million)
Table 205 Middle East & Africa: Minimal Residual Disease Testing Market For Leukemia, By Type, 2024 To 2036 (USD Million)
Table 206 Middle East & Africa: Minimal Residual Disease Testing Market, By Sample Type, 2024 To 2036 (USD Million)
Table 207 Middle East & Africa: Minimal Residual Disease Testing Market, By Customer Type, 2024 To 2036 (USD Million)
Table 208 Recent Developments, By Company, 2023 To 2026
Table 209 Competitive Dashboard: Global Minimal Residual Disease Testing Market
Table 210 Global Minimal Residual Disease Testing Market: Market Share/Ranking Analysis, 2025
Table 211 Natera, Inc.: Product Portfolio
Table 212 Natera, Inc.: Recent Developments
Table 213 Adaptive Biotechnologies Corporation: Product Portfolio
Table 214 Adaptive Biotechnologies Corporation: Recent Developments
Table 215 F. Hoffmann La Roche Ltd.: Product Portfolio
Table 216 F. Hoffmann La Roche Ltd.: Recent Developments
Table 217 Bio Rad Laboratories, Inc.: Product Portfolio
Table 218 Bio Rad Laboratories, Inc.: Recent Developments
Table 219 Illumina, Inc.: Product Portfolio
Table 220 Illumina, Inc.: Recent Developments
Table 221 Thermo Fisher Scientific Inc.: Product Portfolio
Table 222 Thermo Fisher Scientific Inc.: Recent Developments
Table 223 QIAGEN N.V.: Product Portfolio
Table 224 QIAGEN N.V.: Recent Developments
Table 225 Guardant Health, Inc.: Product Portfolio
Table 226 Guardant Health, Inc.: Recent Developments
Table 227 NeoGenomics Laboratories, Inc.: Product Portfolio
Table 228 NeoGenomics Laboratories, Inc.: Recent Developments
Table 229 Myriad Genetics, Inc.: Product Portfolio
Table 230 Myriad Genetics, Inc.: Recent Developments
Table 231 Exact Sciences Corporation: Product Portfolio
Table 232 Exact Sciences Corporation: Recent Developments
Table 233 Integrated DNA Technologies, Inc.: Product Portfolio
Table 234 Integrated DNA Technologies, Inc.: Recent Developments
Table 235 Twist Bioscience Corporation: Product Portfolio
Table 236 Twist Bioscience Corporation: Recent Developments
Table 237 Sysmex Corporation: Product Portfolio
Table 238 Sysmex Corporation: Recent Developments
Table 239 Invivoscribe, Inc.: Product Portfolio
Table 240 Invivoscribe, Inc.: Recent Developments
List of Figures
Figure 1 Market Ecosystem
Figure 2 Key Stakeholders In The MRD Testing Market
Figure 3 Research Process
Figure 4 Key Secondary Sources Referenced For This Study
Figure 5 Primary Research Techniques
Figure 6 Breakdown Of Primary Interviews (Supply Side & Demand Side)
Figure 7 Market Sizing & Growth Forecast Approach
Figure 8 Global Minimal Residual Disease Testing Market: Key Findings
Figure 9 Global Minimal Residual Disease Testing Market: Segmental Analysis
Figure 10 Global MRD Testing Market, By Offering, 2026 Vs. 2036 (USD Million)
Figure 11 Global MRD Testing Market, By Technology, 2026 Vs. 2036 (USD Million)
Figure 12 Global MRD Testing Market, By Application, 2026 Vs. 2036 (USD Million)
Figure 13 Global MRD Testing Market, By Sample Type, 2026 Vs. 2036 (USD Million)
Figure 14 Global MRD Testing Market, By Customer Type, 2026 Vs. 2036 (USD Million)
Figure 15 Global MRD Testing Market, By Geography, 2026 Vs. 2036 (USD Million)
Figure 16 Impact Analysis Of Market Dynamics
Figure 17 Porter's Five Forces Analysis
Figure 18 Technology Evolution Roadmap
Figure 19 Global Minimal Residual Disease Testing Market, By Offering, 2026 Vs. 2036 (USD Million)
Figure 20 Global Minimal Residual Disease Testing Market, By Technology, 2026 Vs. 2036 (USD Million)
Figure 21 Global Minimal Residual Disease Testing Market, By Application, 2026 Vs. 2036 (USD Million)
Figure 22 Global Minimal Residual Disease Testing Market, By Sample Type, 2026 Vs. 2036 (USD Million)
Figure 23 Global Minimal Residual Disease Testing Market, By Customer Type, 2026 Vs. 2036 (USD Million)
Figure 24 Global Minimal Residual Disease Testing Market, By Geography, 2026 Vs. 2036 (USD Million)
Figure 25 North America: Minimal Residual Disease Testing Market Snapshot
Figure 26 Europe: Minimal Residual Disease Testing Market Snapshot
Figure 27 Asia Pacific: Minimal Residual Disease Testing Market Snapshot
Figure 28 Latin America: Minimal Residual Disease Testing Market Snapshot
Figure 29 Middle East & Africa: Number Of New Cancer Cases, By Country
Figure 30 Key Growth Strategies Adopted By Leading Players, 2023 To 2026
Figure 31 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Technology
Figure 32 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Assay Methodology
Figure 33 Minimal Residual Disease Testing Market: Competitive Benchmarking, By Region
Figure 34 Global Minimal Residual Disease Testing Market: Market Share Analysis, 2025
Figure 35 Natera, Inc.: Financial Snapshot
Figure 36 Natera, Inc.: SWOT Analysis
Figure 37 Adaptive Biotechnologies Corporation: Financial Snapshot
Figure 38 Adaptive Biotechnologies Corporation: SWOT Analysis
Figure 39 F. Hoffmann La Roche Ltd.: Financial Snapshot
Figure 40 F. Hoffmann La Roche Ltd.: SWOT Analysis
Figure 41 Bio Rad Laboratories, Inc.: Financial Snapshot
Figure 42 Bio Rad Laboratories, Inc.: SWOT Analysis
Figure 43 Illumina, Inc.: Financial Snapshot
Figure 44 Illumina, Inc.: SWOT Analysis
Figure 45 Thermo Fisher Scientific Inc.: Financial Snapshot
Figure 46 Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 47 QIAGEN N.V.: Financial Snapshot
Figure 48 QIAGEN N.V.: SWOT Analysis
Figure 49 Guardant Health, Inc.: Financial Snapshot
Figure 50 Guardant Health, Inc.: SWOT Analysis
Figure 51 NeoGenomics Laboratories, Inc.: Financial Snapshot
Figure 52 NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 53 Myriad Genetics, Inc.: Financial Snapshot
Figure 54 Myriad Genetics, Inc.: SWOT Analysis
Figure 55 Exact Sciences Corporation: Financial Snapshot
Figure 56 Exact Sciences Corporation: SWOT Analysis
Figure 57 Integrated DNA Technologies, Inc.: Financial Snapshot
Figure 58 Integrated DNA Technologies, Inc.: SWOT Analysis
Figure 59 Twist Bioscience Corporation: Financial Snapshot
Figure 60 Twist Bioscience Corporation: SWOT Analysis
Figure 61 Sysmex Corporation: Financial Snapshot
Figure 62 Sysmex Corporation: SWOT Analysis
Figure 63 Invivoscribe, Inc.: Financial Snapshot
Figure 64 Invivoscribe, Inc.: SWOT Analysis

Companies Mentioned

  • Natera, Inc.
  • Adaptive Biotechnologies Corporation
  • F. Hoffmann La Roche Ltd.
  • Bio Rad Laboratories, Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • QIAGEN N.V.
  • Guardant Health, Inc.
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Exact Sciences Corporation
  • Integrated DNA Technologies, Inc.
  • Twist Bioscience Corporation
  • Sysmex Corporation
  • Invivoscribe, Inc. (U.S.).

Related Topics

Related Reports

Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Liquid Biopsy Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036) - Product Image

Liquid Biopsy Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)

  • Report
  • 295 Pages
  • Global
From
Minimal Residual Disease Testing Market - Global Forecast 2026-2032 - Product Image

Minimal Residual Disease Testing Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Minimal Residual Disease Testing Market Size by Technology, Application, End User, and Region 2026-2034 - Product Image

Minimal Residual Disease Testing Market Size by Technology, Application, End User, and Region 2026-2034

  • Report
  • 140 Pages
  • Global
From
Minimal Residual Disease Market Report 2026 - Product Image

Minimal Residual Disease Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Market

Minimal Residual Disease (MRD) Testing is a type of In Vitro Diagnostics (IVD) used to detect the presence of cancer cells in a patient's body. It is used to monitor the effectiveness of cancer treatments and to detect the recurrence of cancer. MRD testing is typically performed on a sample of bone marrow or peripheral blood, and can detect cancer cells at levels as low as one in a million. It is used to detect the presence of cancer cells in patients with leukemia, lymphoma, and multiple myeloma. MRD testing is a rapidly growing market, driven by the increasing prevalence of cancer and the need for more accurate and sensitive diagnostic tests. The development of new technologies, such as next-generation sequencing and flow cytometry, has enabled more accurate and sensitive MRD testing. Companies in the MRD testing market include Abbott, Agilent Technologies, Bio-Rad Laboratories, Becton Dickinson, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.